Cargando…

Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo‐Controlled, Phase II Study

OBJECTIVE: To determine the effect of selexipag, an oral, selective IP prostacyclin receptor agonist, on the frequency of attacks of Raynaud's phenomenon (RP) in patients with systemic sclerosis (SSc). METHODS: Patients with SSc‐related RP were randomized 1:1 to placebo (n = 38) or selexipag (n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denton, Christopher P., Hachulla, Éric, Riemekasten, Gabriela, Schwarting, Andreas, Frenoux, Jean‐Marie, Frey, Aline, Le Brun, Franck‐Olivier, Herrick, Ariane L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Systemic Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099416/ https://www.ncbi.nlm.nih.gov/pubmed/29193819 http://dx.doi.org/10.1002/art.40242

Ejemplares similares

A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis–Related Raynaud's Phenomenon
por: Wilkinson, Jack D., et al.
Publicado: (2018)

Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis
por: Sobanski, Vincent, et al.
Publicado: (2019)

Ultrasound quantitative assessment of ventral finger microvasculopathy in systemic sclerosis with Raynaud’s phenomena: a comparative study
por: Nam, Kibo, et al.
Publicado: (2023)

Molecular Basis for Dysregulated Activation of NKX2‐5 in the Vascular Remodeling of Systemic Sclerosis
por: Dritsoula, Athina, et al.
Publicado: (2018)

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2021)

Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial
por: Khanna, Dinesh, et al.
Publicado: (2020)

Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study
por: Cutolo, Maurizio, et al.
Publicado: (2016)

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis
por: Allanore, Yannick, et al.
Publicado: (2020)

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
por: Acosta-Herrera, Marialbert, et al.
Publicado: (2021)

Does the Clinical Context Improve the Reliability of Rheumatologists Grading Digital Ulcers in Systemic Sclerosis?
por: Hughes, M., et al.
Publicado: (2016)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
por: Clark, Kristina Elizabeth Neergaard, et al.
Publicado: (2023)

Failed Degradation of JunB Contributes to Overproduction of Type I Collagen and Development of Dermal Fibrosis in Patients With Systemic Sclerosis
por: Ponticos, Markella, et al.
Publicado: (2015)

Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort
por: Kuster, Simon, et al.
Publicado: (2022)

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression
por: Khanna, Dinesh, et al.
Publicado: (2023)

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Systemic sclerosis: state of the art on clinical practice guidelines
por: Smith, Vanessa, et al.
Publicado: (2018)

Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis
por: Becker, Mike, et al.
Publicado: (2019)

Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort
por: Wu, Wanlong, et al.
Publicado: (2019)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Rituximab in early systemic sclerosis
por: Boonstra, Maaike, et al.
Publicado: (2017)

Haematopoietic stem cell transplantation in systemic sclerosis
por: Walker, Ulrich A, et al.
Publicado: (2018)

Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients
por: Beretta, Lorenzo, et al.
Publicado: (2020)

Anticentromere Antibody Levels and Isotypes and the Development of Systemic Sclerosis
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Induction of Inflammation and Fibrosis by Semaphorin 4A in Systemic Sclerosis
por: Carvalheiro, Tiago, et al.
Publicado: (2019)

Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis
por: Martin, Mickaël, et al.
Publicado: (2019)

Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis
por: Ariani, Alarico, et al.
Publicado: (2019)

A stretchable hardness sensor for the assessment of skin disease in systemic sclerosis
por: Wang, Xiuyuan, et al.
Publicado: (2023)

Cardiovascular outcomes in systemic sclerosis with abnormal cardiovascular MRI and serum cardiac biomarkers
por: Dumitru, Raluca B, et al.
Publicado: (2021)

Work Productivity and Economic Burden of Systemic Sclerosis in a Multiethnic Asian Population
por: Xiang, Ling, et al.
Publicado: (2022)

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016)

Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies
por: Liem, Sophie I E, et al.
Publicado: (2023)

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
por: Ayoglu, Burcu, et al.
Publicado: (2023)

Risk of kidney failure in patients with systemic sclerosis: a nationwide population-based study
por: Kwon, Oh Chan, et al.
Publicado: (2023)

Sex-specific difference in cardiac function in patients with systemic sclerosis: association with cardiovascular outcomes
por: Gegenava, Tea, et al.
Publicado: (2023)

Induced antibodies directed to the angiotensin receptor type 1 provoke skin and lung inflammation, dermal fibrosis and act species overarching
por: Yue, Xiaoyang, et al.
Publicado: (2022)

New risk model is able to identify patients with a low risk of progression in systemic sclerosis
por: van Leeuwen, Nina Marijn, et al.
Publicado: (2021)

Latent trajectory modelling of pulmonary artery pressure in systemic sclerosis: a retrospective cohort study
por: Kida, Takashi, et al.
Publicado: (2022)

Spontaneous Pulmonary Hypertension Associated With Systemic Sclerosis in P‐Selectin Glycoprotein Ligand 1–Deficient Mice
por: González‐Tajuelo, Rafael, et al.
Publicado: (2020)

Contribution of Sex and Autoantibodies to Microangiopathy Assessed by Nailfold Videocapillaroscopy in Systemic Sclerosis: A Systematic Review of the Literature
por: van Leeuwen, Nina M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_42am59jm59pipj5ov4hqdb6fj5